TY - JOUR
T1 - High-dose cyclophosphamide for aplastic anemia and autoimmunity
AU - Brodsky, Robert A.
PY - 2002/3/28
Y1 - 2002/3/28
N2 - High-dose cyclophosphamide was developed as a conditioning regimen for allogeneic bone marrow transplantation. Later, it was discovered that high-dose cyclophosphamide spares early hematopoietic stem cells because of their relatively high levels of the enzyme aldehyde dehydrogenase; thus, high-dose cyclophosphamide is a potent immunosuppressive agent, but nonmyeloablative. Recent reports demonstrate that high-dose cyclophosphamide without bone marrow transplantation induces durable treatment-free remissions in severe aplastic anemia and a variety of other autoimmune disorders; however, there is lingering concern about the safety of this approach.
AB - High-dose cyclophosphamide was developed as a conditioning regimen for allogeneic bone marrow transplantation. Later, it was discovered that high-dose cyclophosphamide spares early hematopoietic stem cells because of their relatively high levels of the enzyme aldehyde dehydrogenase; thus, high-dose cyclophosphamide is a potent immunosuppressive agent, but nonmyeloablative. Recent reports demonstrate that high-dose cyclophosphamide without bone marrow transplantation induces durable treatment-free remissions in severe aplastic anemia and a variety of other autoimmune disorders; however, there is lingering concern about the safety of this approach.
UR - http://www.scopus.com/inward/record.url?scp=0036128268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036128268&partnerID=8YFLogxK
U2 - 10.1097/00001622-200203000-00001
DO - 10.1097/00001622-200203000-00001
M3 - Review article
C2 - 11880702
AN - SCOPUS:0036128268
VL - 14
SP - 143
EP - 146
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
SN - 1040-8746
IS - 2
ER -